China Industrial Economy Information Network Finance and Economics Channel learned that recently, China Luckys Group Limited (hereinafter referred to as China Luckys) will be held by the direct thermal imaging silver salt digital medical film patented technology and other 27 intangible assets (including 2 patents and 25 pieces of proprietary technology, hereinafter referred to as the subject assets) listed for transfer, according to the appraisal agency issued the "appraisal report," the appraisal base date is May 31, 2020, the market value of the Subject Assets was appraised using two appraisal methods, namely the cost method and the income method, respectively, on the premise of the open market, in conjunction with the actual situation of the Subject Assets and taking into account various influencing factors, and the appraisal conclusions were based on the appraisal results of the income method. As of the appraisal reference date, the market value of the subject assets is RMB 13,457,900,000, with an appreciation of RMB 13,457,900,000, and the listing deadline is September 9, 2020.
In order to accelerate the development of its subsidiary, Lucky Medical Technology Limited (hereinafter referred to as Lucky Medical), and to better accomplish the goal of serialization of medical dry film products, Lucky decided to participate in the bidding for the listing and transfer of China Lucky's patented medical film technology. on August 26, 2020, the fifth meeting of the eighth session of the Board of Directors of Lucky held by Lucky decided to consider and unanimously adopted the following "Motion on Bidding for the Patented Technology of Direct Thermal Imaging Silver Salt Digital Medical Film of China Lucky Group Limited".
The main direction of Lucky Film is image information materials, new energy materials, and its main products are solar cell backsheets, color photo paper, medical dry film, inkjet printing paper, medicinal fluid for information image material processing, and lithium-ion battery separators. Lekai medical mainly engaged in information chemicals, fine chemicals, as well as medical devices, such as the development, production and sales, registered capital of 130 million yuan, total assets of 418 million yuan, net assets of 359 million yuan. 2020 first half of the year, Lekai medical operating income of 219 million yuan, total profit of 29.49 million yuan, net profit of 26.7922 million yuan.
It is reported that in the first half of 2020, the epidemic profoundly affected the image output market. 2.79 million pairs of people registered for marriage nationwide in the first quarter of 2020, a decline of 46% compared with 2019. 3.15 billion passenger trips were made nationwide in the January-May period, a year-on-year contraction of 56.9%. The professional enlargement and residential photo markets were hit at the same time, with market demand falling by more than 50% in the first half of the year. Lekai film in the first half of the enterprise products, especially the sales revenue of imaging products fell significantly, corporate profitability is reduced. 2020 first half, Lekai film realized operating income of 869 million yuan, a year-on-year decline of 19.58%; to achieve net profit attributable to shareholders of listed companies net 27.8977 million yuan, a year-on-year decrease of 38.83%.
It can be seen that the search for new profit growth point has become the focus of the work of Lucky Film at this stage. In the face of the unfavorable situation of the domestic image market, Lucky Film's image sales take the path of reducing customer costs, increasing product value and other paths to promote sales, planning for the launch of new products, vigorously promote cost-cutting measures, the creation of the "traceability code" quality certification albums, and remotely for a number of environmentally friendly printing workshop to provide technical guidance and services, and so on. Luckyfilm refined the promotion plan of cloud film and cloud image, realized the embedding of cloud film software in the new version of self-service system, optimized the software and hardware of self-service system, and pushed forward the rapid development of cloud service. In the medical and industrial film market, we actively adjusted our sales measures in response to the impact of the epidemic, and our product sales steadily recovered.
The acquisition of the patented technology successfully imported and industrialized will serve as a technical benchmark product for Lucky Medical to enter the mid- and high-end market, which can enrich the product series, help to open up the market and enhance market share, thus bringing revenue and profit growth for Lucky Film. If Lucky Medical successfully introduces direct thermal imaging silver salt digital medical film to the market, it can promote the series development of medical film products, provide customers with medium and high-end product choices, and enhance the quality experience of users. At the same time, it can also greatly increase Lucky Medical's market share in the field of imaging consumables output, in the current increasingly fierce competition, product serialization is conducive to improving the profitability of Lucky Film, thus promoting the realization of the overall planning objectives of the future.
After this transaction, Lucky Medical will obtain all the property rights of the subject intangible assets, and China Lucky will no longer use this intangible asset. The above-bid assets are amortized over 7 years into Lucky Film's future product costs and expenses. However, the relevant technology has industrialization conditions, not yet mass production, there is a risk of unsuccessful technology transformation.
Transferred from: China Industrial Economy Information Network